101 |
Regulation of DNA damage responses by the Myc oncogene : implications for future anti-cancer therapiesHöglund, Andreas January 2011 (has links)
Myc is a transcription factor frequently found deregulated in human cancer. Cells with deregulated expression of Myc carry a selective advantage against its neighbours due to the fact that Myc-mediated transcription governs crucial cellular events such as proliferation and growth. In addition, Myc has been implicated in several other aspects of tumour biology like cellular immortality, the formation of new blood vessels and the colonization of distant tissues through the process of metastasis. Therapy aimed at disrupting essential pathways regulated by Myc is important because of the many different types of cancers that depend on continued signalling along these pathways. This thesis describes new treatment opportunities for cancers with a high Myc signature. In Paper Ι, we describe a new role for the DNA methyltransferase inhibitor Decitabine in the treatment of Myc transformed tumours cells. We show that the therapeutic potential of Decitabine in the treatment of Burkitt Lymphoma relies not only on its ability to cause reactivation of silenced genes such as pro-apoptotic PUMA, but also on the DNA damage that this drug induces. In vivo, Decitabine delays disease progression of transplanted lymphoma cells. In Paper ΙΙ, we identify the DNA damage checkpoint kinase Chk1 as a therapeutic target in Myc overexpressing cancers. We show that targeting Chk1 with shRNA or with a novel small molecule inhibitor cause a delay in disease progression of transplanted lymphoma cells in vivo. In Paper ΙΙΙ, the Chk1-related kinase Chk2 is evaluated as a therapeutic target in Myc overexpressing cancers. Myc overexpressing cells are not dependent on Chk2 but we show that Chk2 abrogation using shRNA causes polyploidization and protection against DNA damage. However, Chk2-targeted therapy elicits a synergistic lethal response in combination with inhibition of the DNA repair associated protein PARP. In conclusion, this thesis shows the potential of targeting the DNA damage machinery and the functional hubs important for maintenance of genomic stability in tumours with a deregulated expression of Myc.
|
102 |
Assessment of therapeutic targets in experimental models of Myc-induced lymphomaPlym Forshell, Linus January 2011 (has links)
The Myc transcription factor activates expression of genes that promote cellular functions such as proliferation and cell growth. The deregulated Myc expression, characteristic for the tumor cell, also activates apoptosis, which selects for additional genetic changes deactivating the induced cell death. However, the continuous overexpression of Myc can also be a liability for a tumor, which can be taken advantage of in cancer treatment. In Paper I, we describe a new way of using the DNA methyltransferase inhibitor Decitabine, in treating Myc overexpressing tumors. We show that Decitabine treatment activates cell death by reactivating silenced tumor suppressors such as Puma, but also by inducing DNA damage. Decitabine treatment of Myc driven lymphomas is also shown to prolong disease free survival in mouse models. Myc driven transformation requires a collaborative deregulation of genes. The family of Pim kinases has been shown to collaborate with Myc in tumorigenesis. In Paper II, we show that the Pim-3 kinase protein is highly expressed in many Myc overexpressing lymphomas from Myc transgenic mice as well as human Burkitt Lymphoma samples. The Pim-3 locus is shown to interact with the Myc protein and be a direct target for Myc activated transcription. Additionally, we demonstrate that the Pim kinase inhibitor, Pimi, targeting the Pim kinase family (Pim-1, Pim-2 and Pim-3), induce a cell death that is mediated by, but not dependent on caspase activity. The Pimi induced cell death was potentiated when combined with RNAi knockdown of the casein kinase II (CK2) protein. In paper III, we describe the development of a somatic mouse model for lymphomagenesis, utilizing the RCAS-tva technology. We show that primary B cells from these mice are transducible and transformed when infected with a combination of RCAS- HA tagged Myc, KRasV12D and human Bcl-XL virus. In conclusion, we show that the labile milieu created by the deregulated expression of Myc facilitates new approaches in treatment of Myc overexpressing tumors. Also, our new tva mouse model show promise in modeling lymphomagenesis.
|
103 |
Downstream targets of the oestrogen receptor and endocrine resistanceMcNeil, Catriona Mairi, Garvan Institute of Medical Research, Faculty of Medicine, UNSW January 2008 (has links)
The transcription factor c-Myc is an early downstream target of oestrogen action in breast cancer cells in culture and it has been speculated that aberrant c-Myc expression may mediate antioestrogen resistance. However, studies of c-Myc protein expression as either a prognostic or predictive marker in human breast cancer have been limited and contradictory, as have been studies of c-Myc expression during breast cancer evolution. In order to assess the relationship between c-Myc protein expression and outcome from breast cancer, a representative cohort of 292 women with invasive ductal carcinoma (IDC) and linked clinicopathological data was assembled and tissue microarrays (TMA) generated from the archived breast cancer specimens. Detailed assessments of the expression of cyclin D1, cyclin E, p21WAF1/Cip1 and p27Kip1 were also conducted and analysed in relation to c-Myc expression using immunohistochemistry. Changes in c-Myc protein expression in a TMA model of breast cancer evolution were also conducted. Finally the cell-cycle effects of low-level constitutive c-Myc expression and high-level inducible c-Myc expression were evaluated in MCF-7 cells in vitro. Key novel results obtained were that c-Myc protein expression changed from preferentially nuclear to preferentially cytoplasmic during the evolution of breast cancer. In women with early invasive breast carcinoma, a "high-risk" cytoplasmic predominant c-Myc expression pattern was defined (~13% of cases) that independently predicted for poor outcome generally, among ER positive cases and in ER postive cases treated with endocrine therapy. In vitro studies confirmed that c-Myc overexpression was associated with resistance to the anti-proliferative effects of anti-oestrogens with persistence of both cyclin D1-cdk4 and cyclin E-cdk2 activities in the face of anti-oestrogen treatment. Further novel findings were that high cyclin D1 expression (upper 10% of expressors) was an independent predictor of poor outcome among ER positive breast cancer cases. Amongst ER + PR positive cases, both "high-risk" c-Myc expression and high level cyclin D1 expression were independent predictors of poor outcome. In summary, these data indicate that aberrant expression of the cell cycle proteins c-Myc and cyclin D1 may result in poor breast cancer outcomes in hormone receptor positive breast cancer and reinforces the importance of the cell cycle as a potential site of therapeutic manipulation in endocrine-resistant breast cancer.
|
104 |
Participação das vias atm/atr e c-myc/gsh nos efeitos antitumorais da cordiaquinona J induzidos pelo estresse oxidativo / Participation of atm/atr and c-myc/gsh pathways in the antitumor effects of cordiaquinone J induced by oxidative stressMarinho Filho, José Delano Barreto January 2012 (has links)
MARINHO FILHO, José Delano Barreto. Participação das vias ATM/ATR e C-MYC/GSH nos efeitos antitumorais da cordiaquinona J induzidos pelo estresse exidativo. 2012. 173 f. Tese (Doutorado em Farmacologia) - Universidade Federal do Ceará. Faculdade de Medicina, Fortaleza, 2012. / Submitted by denise santos (denise.santos@ufc.br) on 2013-07-29T13:38:12Z
No. of bitstreams: 1
2012_tese_jdbmarinhofilho.pdf: 3406223 bytes, checksum: 3c7724cbd89a3ac8cea011d4b36c1188 (MD5) / Approved for entry into archive by Erika Fernandes(erikaleitefernandes@gmail.com) on 2013-08-06T11:56:33Z (GMT) No. of bitstreams: 1
2012_tese_jdbmarinhofilho.pdf: 3406223 bytes, checksum: 3c7724cbd89a3ac8cea011d4b36c1188 (MD5) / Made available in DSpace on 2013-08-06T11:56:33Z (GMT). No. of bitstreams: 1
2012_tese_jdbmarinhofilho.pdf: 3406223 bytes, checksum: 3c7724cbd89a3ac8cea011d4b36c1188 (MD5)
Previous issue date: 2012 / Cordiaquinones are meroterpenoid naphtoquinones from plants belonging to the genus Cordia with several described biological activities, including antifungal, larvicidal and cytotoxic effects. The aim of this study was to evaluate the anticancer potential of a cordiaquinone isolated from the roots of Cordia leucocephala plant. The present study evaluated the cytotoxic potential of cordiaquinone J in several tumor and normal cell lines by MTT assay and its possible mechanism of action. The study of the mechanism of action of cordiaquinones L and M, in human leukemia cells (HL-60) showed induction of cell death by apoptosis, and these effects were related to the induction of oxidative stress. Then the study was continued only with the cordiaquinone J. The cordiaquinone J showed IC50 values ranging from 4.6 to 6.8μM in leukemia cells and 33.6 to 37 μM in normal cells, after 24 hours of incubation. In HL-60 cells was observed apoptosis induction preferentially by extrinsic pathway. The induction of DNA damage by cordiaquinone J observed by comet assay was associated with activation of protein kinases of ATM/ATR pathway. The DNA damage, as well as activation of protein kinases via the ATM / ATR was observed in HL-60 cells but not in normal cells. These effects in HL-60 cells may be related to the depletion of protein expression of glutathione and c-myc observed. The anticancer potential was confirmed in vivo through inhibition of sarcoma-180 tumor by 72.5% after the treatment with 50 mg/kg of cordiaquinone J. The pre-treatment of cells or animals with N-acetyl-L-cysteine abolished most of the in vitro and in vivo observed effects, reinforcing the role of reactive oxygen species generation in cordiaquinone J activity. / As cordiaquinonas são naftoquinonas meroterpenóides isolados de plantas pertencentes ao gênero Cordia com várias atividades biológicas descritas, incluindo atividades antifúngica, larvicida e citotóxica. O objetivo deste trabalho foi avaliar o potencial anticâncer de uma cordiaquinona isolada das raízes da planta Cordia leucocephala. O presente estudo avaliou o potencial citotóxico da cordiaquinona J em várias linhagens de células tumorais e normais pelo teste do MTT e seu possível mecanismo de ação. A cordiaquinona J mostrou valores de CI50 variando de 4,6 a 6,8 μM em células leucêmicas e 33,6 a 37 μM em células normais, após 24 horas de incubação. Nas células HL-60 foi observado indução de apoptose preferencialmente pela via extrínseca. A indução do dano ao DNA observado pelo tratamento com a cordiaquinona J através do ensaio do cometa foi associado com a ativação de proteínas quinases da via ATM/ATR. O dano ao DNA, assim como a ativação das proteínas quinases da via ATM/ATR foi visualizado em células HL-60, mas não em células normais. Estes efeitos em HL-60 podem estar relacionados com a depleção da expressão proteica de glutationa e de c-myc observados. O potencial anticâncer foi confirmado in vivo através da inibição do tumor sarcoma-180 em 72,5% após o tratamento com 50 mg/kg de cordiaquinona J. O pré-tratamento tanto das células quanto dos animais com N-acetil-L-cisteina inibiu todos os efeitos observados in vitro e in vivo reforçando o papel da geração das espécies reativas de oxigênio na atividade antitumoral da cordiaquinona J.
|
105 |
ParticipaÃÃo das vias atm/atr e c-myc/gsh nos efeitos antitumorais da cordiaquinona J induzidos pelo estresse oxidativo. / Participation of atm/atr and c-myc/gsh pathways in the antitumor effects of cordiaquinone J induced by oxidative stress.Josà Delano Barreto Marinho Filho 29 October 2012 (has links)
Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / As cordiaquinonas sÃo naftoquinonas meroterpenÃides isolados de plantas pertencentes ao gÃnero Cordia com vÃrias atividades biolÃgicas descritas, incluindo atividades antifÃngica, larvicida e citotÃxica. O objetivo deste trabalho foi avaliar o potencial anticÃncer de uma cordiaquinona isolada das raÃzes da planta Cordia leucocephala. O presente estudo avaliou o potencial citotÃxico da cordiaquinona J em vÃrias linhagens de cÃlulas tumorais e normais pelo teste do MTT e seu possÃvel mecanismo de aÃÃo. A cordiaquinona J mostrou valores de CI50 variando de 4,6 a 6,8 μM em cÃlulas leucÃmicas e 33,6 a 37 μM em cÃlulas normais, apÃs 24 horas de incubaÃÃo. Nas cÃlulas HL-60 foi observado induÃÃo de apoptose preferencialmente pela via extrÃnseca. A induÃÃo do dano ao DNA observado pelo tratamento com a cordiaquinona J atravÃs do ensaio do cometa foi associado com a ativaÃÃo de proteÃnas quinases da via ATM/ATR. O dano ao DNA, assim como a ativaÃÃo das proteÃnas quinases da via ATM/ATR foi visualizado em cÃlulas HL-60, mas nÃo em cÃlulas normais. Estes efeitos em HL-60 podem estar relacionados com a depleÃÃo da expressÃo proteica de glutationa e de c-myc observados. O potencial anticÃncer foi confirmado in vivo atravÃs da inibiÃÃo do tumor sarcoma-180 em 72,5% apÃs o tratamento com 50 mg/kg de cordiaquinona J. O prÃ-tratamento tanto das cÃlulas quanto dos animais com N-acetil-L-cisteina inibiu todos os efeitos observados in vitro e in vivo reforÃando o papel da geraÃÃo das espÃcies reativas de oxigÃnio na atividade antitumoral da cordiaquinona J. / Cordiaquinones are meroterpenoid naphtoquinones from plants belonging to the genus Cordia with several described biological activities, including antifungal, larvicidal and cytotoxic effects. The aim of this study was to evaluate the anticancer potential of a cordiaquinone isolated from the roots of Cordia leucocephala plant. The present study evaluated the cytotoxic potential of cordiaquinone J in several tumor and normal cell lines by MTT assay and its possible mechanism of action. The study of the mechanism of action of cordiaquinones L and M, in human leukemia cells (HL-60) showed induction of cell death by apoptosis, and these effects were related to the induction of oxidative stress. Then the study was continued only with the cordiaquinone J. The cordiaquinone J showed IC50 values ranging from 4.6 to 6.8μM in leukemia cells and 33.6 to 37 μM in normal cells, after 24 hours of incubation. In HL-60 cells was observed apoptosis induction preferentially by extrinsic pathway. The induction of DNA damage by cordiaquinone J observed by comet assay was associated with activation of protein kinases of ATM/ATR pathway. The DNA damage, as well as activation of protein kinases via the ATM / ATR was observed in HL-60 cells but not in normal cells. These effects in HL-60 cells may be related to the depletion of protein expression of glutathione and c-myc observed. The anticancer potential was confirmed in vivo through inhibition of sarcoma-180 tumor by 72.5% after the treatment with 50 mg/kg of cordiaquinone J. The pre-treatment of cells or animals with N-acetyl-L-cysteine abolished most of the in vitro and in vivo observed effects, reinforcing the role of reactive oxygen species generation in cordiaquinone J activity.
|
106 |
The Essential Role of the Non-Essential Amino Acid Asparagine in Lymphoid MalignanciesSrivastava, Sankalp 05 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Cancer cells display increased metabolic demands to support their proliferation and biosynthetic needs. It has been extensively shown in cancers, that amino acids have functions beyond the role of mRNA translation. The breadth of functions makes amino acid restriction an effective strategy for cancer therapy; hence an important line of research involves targeting amino acid acquisition and metabolism therapeutically. Currently, asparagine depletion via L-Asparaginase in acute lymphoblastic leukemia (ALL) remains the only clinically approved therapy to date.
In the first project, we showed that ALL cells are auxotrophic for asparagine and rely on exogenous sources for this non-essential amino acid. However, sensitivity to L-Asparaginase therapy is mitigated by the expression of the enzyme asparagine synthetase (ASNS), involved in de novo asparagine biosynthesis. We showed that this adaptive response requires two essential steps; demethylation of the ASNS promoter and recruitment of activating transcription factor 4 (ATF4) to the promoter to drive ASNS transcription.
Our follow-up study in ALL cells showed that asparagine bioavailability (through de novo biosynthesis or exogenous sources) is essential to maintain the expression of the critical oncogene c-MYC. c-MYC is a potent transcription factor and is dysregulated in over 60% of cancers, including hematopoietic malignancies. We showed that this regulation by asparagine is primarily at the translation level and c-MYC expression is rescued only when exogenous asparagine is available or when cells can undertake de novo biosynthesis. At the biochemical level, asparagine depletion also causes an induction of ATF4 mediated stress response and suppression of global translation mediated by decreased mammalian target of rapamycin complex 1 (mTORC1) activity. However, we found that neither inhibition of the stress response or rescuing global translation rescued c-MYC protein expression. We also extended this observation to c-MYC-driven lymphomas using cell lines and orthotopic in vivo models. We showed that genetic inhibition of ASNS or pharmacological inhibition of asparagine production can significantly limit c-MYC protein and tumor growth when environmental asparagine is limiting.
Overall, our work shows an essential role for asparagine in lymphoid cancers and has expanded on the usage of L-Asparaginase to resistant leukemias and lymphomas.
|
107 |
MOLECULAR RECOGNITION OF C-MYC PROMOTER G-QUADRUPLEX BY NUCLEOLIN PROTEINLuying Chen (16807251) 09 August 2023 (has links)
<p>c-Myc is one of the most important oncogenes. G-quadruplex DNA secondary structure formed in the proximal promoter region of c-Myc functions as a transcription silencer and is targetable by small molecules. Therefore, the c-Myc promoter G-quadruplex (MycG4) is an attractive anticancer drug target. Protein recognition of MycG4 is essential for its transcriptional regulating. Nucleolin was discovered as a major MycG4 binding protein in 2009. It shows a remarkably higher binding affinity for MycG4 over its known substrate NRE_RNA and overexpression of nucleolin represses the activity of the c-Myc promoter. However, little is known about its molecular recognition of MycG4. Here, we use X-ray crystallography combined with other biochemical and biophysical methods to understand how nucleolin recognizes MycG4. Nucleolin is a 77 kD protein with a modular organization. The four RNA-binding domains (RBD) of nucleolin are the minimal domains for high affinity binding with MycG4. We show that nucleolin prefers the c-Myc parallel G-quadruplex with a 6-nt central loop (Myc161) that is the thermodynamically favored conformation. Using a custom G4 DNA microarray, we optimized the MycG4 sequence with over 10-fold increased binding affinity to nucleolin. Fabs are widely used tools to facilitate crystallization and we have discovered Fabs that specifically bind the nucleolin-MycG4 complex using a phage display screening. This approach enabled us to obtain crystals of the nucleolin-MycG4-Fab ternary complex diffracted at 2.6 Å and we determined the crystal structure. In the structure, the parallel MycG4 is very well-defined with two K<sup>+</sup> between the three G-treads. The central 6-nt loop residue protrude from the G4-core and extensively recognized by the nucleolin. Only RBD1 and RBD2 of nucleolin are seen in the crystal structures and interact extensively with the 6-nt central loop and 5′-flanking of MycG4. The binding surface and area of the globular MycG4 by nucleolin is much more extensive than NRE_RNA and involves an extra binding site. Fab binds to both RBD1 and 3′-end of MycG4 to stabilize the complex. The well-defined partial RBD2-3 linker and a cavity close to the 1-nt T19 loop suggest that the missing RBD3 likely binds the 3<sup>rd</sup> loop of MycG4. This structure is the first MycG4-protein complex structure. It will help understand MycG4 and nucleolin interactions and the development of MycG4 targeted cancer therapeutics. This structure also provides novel insights into how proteins recognize the globular G-quadruplexes, highlighting the potential of G-quadruplexes as a platform for multivalent interactions such as with multiple tandem RBDs.</p>
|
108 |
Identifikation synthetisch-letaler Interaktionen mit dem Tumorsuppressor APC und Beeinflussung von MYC-Proteinmengen durch Translationsinhibition im kolorektalen Karzinom / Identification of synthetic lethal interactions with the tumour suppressor APC and Manipulation of MYC protein levels in colorectal cancer by translational inhibitionUthe, Friedrich Wilhelm January 2018 (has links) (PDF)
Der Tumorsupressor APC ist in der Mehrzahl aller Fälle kolorektaler Karzinome bereits in
der initialen Phase der Karzinogenese mutiert. Diese Mutationen führen zu einer aberranten Aktivierung des Wnt-Signalweges sowie zu weiteren die Karzinogenese vorrantreibenden Aktivitäten, beispielsweise einem veränderten Migrationsverhalten. Dieser Dissertation
zu Grunde liegt die Idee, dass durch die Trunkierung des APC-Proteins aber auch Abhängigkeiten von Genaktivitäten entstehen, die zuvor entbehrlich waren. Solche synthetisch
letalen Gene sollten in einem high-content shRNA-Screen gefunden werden.
Für die Durchführung des Screens wurde ein von der SW480 Kolonkarzinomzelllinie
abgeleitetes, isogenes Zellsystem generiert, welches durch Induktion mit Doxyzyklin das
vollständige APC-Allel (FL-APC) exprimiert. Infolge dieser Expression zeigen die Zellen
einen weniger malignen Phänotyp. Dies spiegelt sich darin wider, dass die Zellen durch
FL-APC Expression in ihrer Wnt-Signalwegsaktivität eingeschränkt werden. Doxyzyklininduzierte Zellen sind schlechter in der Lage ohne Adhäsion zu proliferieren als nicht induzierte Zellen. Andererseits ist ihre Fähigkeit einem FKS-gradienten entlang zu migrieren
verbessert.
Der shRNA-Screen wurde mit der Decipher shRNA-Bibliothek durchgeführt. Diese
enthält 27.500 verschiedene shRNAs mit Interferenzaktivität gegen 5.000 mRNAs, die potentiell pharmakologisch inhibierbare Proteine kodieren. Die besten zwei Kandidaten für
eine synthetisch letale Interaktion mit trunkiertem APC, BCL2L1 und EIF2B5 wurden im
Verlauf einer Masterarbeit bzw. direkt in dieser Disseration validiert. EIF2B5 zeigte in vitro nach Depletion durch unterschiedliche shRNAs einen di erentiellen Proliferationse ekt
bei FL-APC induzierten im Vergleich zu kontrollbehandelten Zellen. Dieser di erentielle
E ekt konnte in einem weiteren Modellsystem, SW480 Zellen mit konstitutiver FL-APC
Expression, ebenfalls validiert werden.
Durch Expression einer shRNA mit Aktivität gegen EIF2B5 werden in beiden Zellsystem die unfolded protein response (UPR) Gene DDIT3 und splXBP1 aktiviert. Interessanterweise werden durch die Expression von FL-APC diese Gene reprimiert. Im Promotor
der EIF2B5-mRNA be ndet sich eine Bindestelle für MYC. Es ist denkbar, dass durch die
Expression von FL-APC eine globale Veränderung der Genexpression vorgenommen wird,
die einerseits eine Repression von EIF2B5 nach sich zieht aber andererseits eine hierdurch
ausgelöste ER-Stress Antwort verhindert. Eine Inhibition von EIF2B5 ohne diese Adaption
andererseits führt nach diesem Model zu einer UPR-aktivierten Apoptose.
In einem zweiten Projekt wurde das überraschende Verhalten von Kolonkarzinomzellen untersucht, die nach Zugabe von BEZ235, einem dualen PI3K/mTOR Inhibitor, trotz
gegenteiliger Erwartungen MYC-Proteinmengen erhöhen. Eine Repression wurde erwar-
tet, weil die Inhibition von PI3K einerseits zu einer proteasomalen Destabiliserung und
andererseits die mTOR Inhibition zu einer verringerten Synthese von MYC führen sollte.
Während bereits gezeigt werden konnte, dass durch einen FOXO-vermittelten Mechanismus MAPK-abhängig die MYC-Expression verstärkt wird, wurde in dieser Dissertation
die erwartete Translationsinhibition untersucht. BEZ235 inhibiert zwar CAP-abhängige
Translation, das MYC Protein wird jedoch aufgrund einer IRES-vermittelten Translation
weiterhin exprimiert. Silvestrol, ein Inhibitor der Helikase eIF4A andererseits interveniert
mit CAP- und IRES-abhängiger Translation und kann die MYC-Proteinkonzentrationen
verringern. Wir konnten zudem feststellen, dass die Applikation von Silvestrol auch in vivo
möglich und wirksam ist und zudem tolleriert wird. Dies gibt Anlass zur Ho nung, dass
eine Intervention der Translation auch im Menschen eine valide Strategie zur Behandlung
MYC-getriebener Tumore sein könnte. / The tumorsupressor APC is mutated in initiating colorectal cancers. These mutations
lead to an aberrant actiavation of the wnt-signaling pahtway and to further carcinogenic
activities such as altered migration behaviour. The idea that novel dependencies upon
previously expendable genes are generated through APC-mutations form the basis of this
disseration. These so called synthetic lethal Genes were searched for harnessing a high
content shRNA screen.
We generated an isogenic cell system which was deviated from the colorectal cancer cell
line SW480. These cells naturally express truncated APC. The generated system expresses a
full-lenght allele upon doxycycline exposure. SW480 cells which are induced partially revert
their malignancy. Ancorage independend growth is compromised and migration along a
gradient of fetal calf serum is improved.
The Decipher shRNA library was used for screening. It consists of 27.500 di erent
shRNAs intefering with the activity of 5.000 genes which are potantially drugable. The
two best candidates scoring as hits in the screen were EIF2B5 and BCL2L1. BCL2L1 was
validated in a cooperating masterthesis and EIF2B5 could be validated in the course of
this diseration. Following EIF2B5 depletion using di erent shRNA constructs, we were
able to see di erential behaviour in pTRE-APC cells as well as in a second model system
in which FL-APC was expressed constitutively.
Interestingly an activation of the ER-Stress genes DDIT3 and splXBP1 can be seen after EIF2B5 depletion. These genes are repressed, when FL-APC ist expressed. The EIF2B5
promotor has a MYC-binding site and we speculate, that FL-APC expression induces a
genetic program which represses EIF2B5 on the one hand, however prohibits the ER-Stress
reaction which follows this trigger. Inhibtion of EIF2B5 without this global adaption in
genexpression on the other side initiates UPR-mediated apoptosis.
In a second project, the suprising behaviour of colon carcinoma cell lines, which upregulate MYC upon BEZ235 exposure was examined. The dual inhibitor was thought to
downregulate MYC through its PI3K and mTOR inhibitory acitivites which were thought
to destabilise and MYC and prohibit it's expression, respectively. Whereas former work
could demonstrate a FOXO-mediated, MAPK-dependend positive MYC-gene expression
clue the aim of this thesis was to analyse the expecte protein tranlational inhibition. Indeed,
BEZ235 inhibits CAP-dependend translation, however the MYC protein is still translated
through IRES-dependend translation. The eIF4A-inhibitor Silvestrol intervenes with both
CAP- and IRES-dependend translation and can therefore reduce MYC protein levels
|
109 |
MYC shapes the composition of RNA polymerase II through direct recruitment of transcription elongation factors / MYC beeinflusst die Zusammensetzung der RNA-Polymerase II durch die direkte Rekrutierung von Transkriptions-ElongationsfaktorenHofstetter, Julia Eva Ines January 2022 (has links) (PDF)
The transcription factor MYC is a onco-protein, found to be deregulated in many human cancers. High MYC levels correlate with an aggressive tumor outcome and poor survival rates. Despite MYC being discovered as an oncogene already in the 1970s, how MYC regulates transcription of its target genes, which are involved in cellular growth and proliferation, is not fully understood yet.
In this study, the question how MYC influences factors interacting with the RNA polymerase II ensuring productive transcription of its target genes was addressed using quantitative mass spectrometry. By comparing the interactome of RNA polymerase II under varying MYC levels, several potential factors involved in transcriptional elongation were identified. Furthermore, the question which of those factors interact with MYC was answered by employing quantitative mass spectrometry of MYC itself. Thereby, the direct interaction of MYC with the transcription elongation factor SPT5, a subunit of the DRB-sensitivity inducing factor, was discovered and analyzed in greater detail. SPT5 was shown to be recruited to chromatin by MYC. In addition, the interaction site of MYC on SPT5 was narrowed down to its evolutionary conserved NGN-domain, which is the known binding site for SPT4, the earlier characterized second subunit of the DRB-sensitivity inducing factor. This finding suggests a model in which MYC and SPT4 compete for binding the NGN-domain of SPT5.
Investigations of the SPT5-interacting region on MYC showed binding of SPT5 to MYC’s N-terminus including MYC-boxes 0, I and II.
In order to analyze proteins interacting specifically with the N-terminal region of MYC, a truncated MYC-mutant was used for quantitative mass spectrometric analysis uncovering reduced binding for several proteins including the well-known interactor TRRAP and TRRAP-associated complexes.
Summarized, ... / Bei dem Transkriptionsfaktor MYC handelt es sich um ein Onkoprotein, welches in einer Vielzahl der menschlichen Krebserkrankungen in erhöhter Konzentration vorliegt, was wiederum mit einem schweren Krankheitsverlauf einhergeht. Bereits in den 1970iger Jahren wurde das Protein MYC als ein Onkoprotein identifiziert, aber wie es die Transkription seiner großen Bandbreite an Zielgenen, welche für Zellwachstum und -proliferation verantwortlich sind, reguliert, ist bisher noch nicht eindeutig geklärt.
In dieser Arbeit wurde die zentrale Frage untersucht, wie MYC die Proteine beeinflusst, die mit der RNA-Polymerase II interagieren, um dadurch eine schnelle und produktive Transkription seiner Zielgene zu ermöglichen. Hierfür wurden mittels der Durchführung massenspektrometrischer Untersuchungen Proteine, die in der An- und Abwesenheit von MYC mit der RNA-Polymerase II interagieren, identifiziert, was eine MYC-bedingte Änderung einiger Elongationsfaktoren im Interaktom der RNA-Polymerase II aufzeigte. Des Weiteren wurden ebenfalls unter Zuhilfenahme massenspektrometrischer Analysen Proteine bestimmt, die mit MYC selbst interagieren. Hierdurch konnte die bisher unbeschriebene, direkte Interaktion zwischen MYC und SPT5, der großen Untereinheit des DRB-sensitivity inducing factors, aufgedeckt und näher analysiert werden. Es konnte gezeigt werden, dass MYC SPT5 zum Chromatin rekrutiert. Weiter konnte nachgewiesen werden, dass MYC mit der evolutionär konservierten NGN-Domäne von SPT5 interagiert, an welche auch SPT4, die zweite Untereinheit des DRB-sensitivity inducing factors, bindet. Dies resultiert in dem Modell, dass MYC mit SPT4 um die Bindestelle auf SPT5 konkurriert und durch dieses ersetzt werden kann.
Die Nähere Untersuchung der Bindestelle von SPT5 auf MYC zeigte eine Binderegion im N-terminalen Bereich von MYC auf, der die MYC-Boxen 0, I und II miteinschließt.
Um Proteine zu identifiziert, die selektiv mit dem N-terminalen Bereich von MYC interagieren, ...
|
110 |
The role of BRCA1 and DCP1A in the coordination of transcription and replication in neuroblastoma / Die Rolle von BRCA1 und DCP1A in der Koordination von Transkription und Replikation im NeuroblastomKalb, Jacqueline January 2021 (has links) (PDF)
The deregulation of the MYC oncoprotein family plays a major role in tumorigenesis and tumour maintenance of many human tumours. Because of their structure and nuclear localisation, they are defined as undruggable targets which makes it difficult to find direct therapeutic approaches. An alternative approach for targeting MYC-driven tumours is the identification and targeting of partner proteins which score as essential in a synthetic lethality screen.
Neuroblastoma, an aggressive entity of MYCN-driven tumours coming along with a bad prognosis, are dependent on the tumour suppressor protein BRCA1 as synthetic lethal data showed. BRCA1 is recruited to promoter regions in a MYCN-dependent manner. The aim of this study was to characterise the role of BRCA1 in neuroblastoma with molecular biological methods.
BRCA1 prevents the accumulation of RNA Polymerase II (RNAPII) at the promoter region. Its absence results in the formation of DNA/RNA-hybrids, so called R-loops, and DNA damage. To prevent the accumulation of RNAPII, the cell uses DCP1A, a decapping factor known for its cytoplasmatic and nuclear role in mRNA decay. It is the priming factor in the removal of the protective 5’CAP of mRNA, which leads to degradation by exonucleases. BRCA1 is necessary for the chromatin recruitment of DCP1A and its proximity to RNAPII. Cells showed upon acute activation of MYCN a higher dependency on DCP1A. Its activity prevents the deregulation of transcription and leads to proper coordination of transcription and replication. The deregulation of transcription in the absence of DCP1A results in replication fork stalling and leads to activation of the Ataxia telangiectasia and Rad3 related (ATR) kinase. The result is a disturbed cell proliferation to the point of increased apoptosis. The activation of the ATR kinase pathway in the situation where DCP1A is knocked down and MYCN is activated, makes those cells more vulnerable for the treatment with ATR inhibitors.
In summary, the tumour suppressor protein BRCA1 and the decapping factor DCP1A, mainly known for its function in the cytoplasm, have a new nuclear role in a MYCN-dependent context. This study shows their essentiality in the coordination of transcription and replication which leads to an unrestrained growth of tumour cells if uncontrolled. / Die MYC Onkoproteine spielen in einer Vielzahl humaner Tumore eine entscheidende Rolle und sind in fast allen Fällen dereguliert. Aufgrund ihrer Struktur und Lokalisation im Zellkern gelten sie für die Arzneimittelentwicklung als therapeutisch schwer angreifbar. Der Ansatz der synthetischen Lethalität ist es, Partnerproteine zu finden, die gerade für MYC-getriebene Tumore essenziell sind und diese zu inhibieren.
Neuroblastome, die in einer besonders aggressiven Entität durch eine MYCN-Amplifikation getrieben sind und damit mit einer schlechten Prognose einhergehen, sind abhängig vom Tumorsupressor BRCA1, wie Daten zur synthetischen Lethalität zeigten. BRCA1 wird in Abhängigkeit von MYCN zu Promotoren rekrutiert. Diese Arbeit diente daher der Charakterisierung der Funktionalität von BRCA1 im Neuroblastom.
BRCA1 verhindert die Akkumulation von RNA Polymerase II (RNAPII) in der Promoterregion. Ist BRCA1 nicht präsent, führt dies zur Bildung von DNA/RNA-Hybriden, sogenannten R-loops, und zu DNA Schäden. Um die Akkumulation von RNAPII zu verhindern, nutzt die Zelle DCP1A, einen Decapping Faktor, der sowohl im Cytoplasma als auch im Nukleus eine Rolle im mRNA Abbau spielt. DCP1A entfernt den schützenden 5’CAP der mRNA, wodurch diese von Exonukleasen abgebaut wird. BRCA1 ist notwendig für die Chromatin Bindung von DCP1A und die Rekrutierung zu RNAPII. Zellen mit einer akuten Aktivierung des MYCN Onkoproteins zeigen eine erhöhte Abhängigkeit von DCP1A. DCP1A verhindert eine Deregulation der Transkription, um Transkription mit Replikation erfolgreich zu koordinieren. Andernfalls führt dies beim Verlust von DCP1A zur Blockierung von Replikationsgabeln und der Aktivierung der Ataxia telangiectasia and Rad3 related (ATR) Kinase führt. In der Folge ist das Zellwachstum gestört und Zellen gehen vermehrt in Apoptose. Die Aktivierung des ATR Signalweges beim Verlust von DCP1A und MYCN Aktivierung verhindert vorerst den Zelltod, wodurch diese Zellen jedoch sensitiver auf die Inhibition von ATR reagieren.
Zusammenfassend lässt sich sagen, dass BRCA1 als Tumorsupressor und DCP1A als Decapping Faktor, hauptsächlich beschrieben als cytoplasmatisches Protein, eine entscheidende nukleäre Rolle in der Situation einer akuten Aktivierung von MYCN spielen. Dort sind sie essenziell um Transkription mit Replikation zu koordinieren und damit zu einem ungebremsten Wachstum der Tumorzellen beizutragen.
|
Page generated in 0.0857 seconds